The delay follows leadership changes within the FDA. Dr. Scott Steele has been appointed acting director of the agency’s ...

In the wake of unprecedented workforce cuts at the FDA, former Commissioner Scott Gottlieb and an unnamed former CBER ...

One of the FDA’s recently departed top officials is weighing in on the wide-ranging staff cuts at the agency and how they ...

Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

Novavax shifts to a partnership-focused strategy with a $500M Sanofi deal. Despite regulatory and competitive risks. See why ...

Health secretary Robert F. Kennedy Jr. has expressed another unorthodox view on vaccines, declaring that single antigen ...

In an emailed statement to The Fly, Novavax (NVAX) said, “As we have previously stated, we believe that our Biologics License Application for ...

After the gutting of the Department of Health and Human Services, fears mount about the future direction of the FDA—with ...

Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID shot approval delay.

But full FDA approval would allow the vaccine to ... alternative to mRNA COVID-19 vaccines for the US,” Novavax added. The delay comes as the FDA is undergoing leadership changes.

The delay dovetails with moves by Republican lawmakers in at least seven states to ban or limit mRNA vaccines. Some, according to KFF Health News, are also pressing regulators to revoke federal ...